Full Press Release Details
on Timings and Corporate Actions
York/London, 30 July 2020 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA) ("Tiziana"
or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious
diseases, gives the following updates on corporate actions:
has been closed for issuances and cancellations of the Company's American Depositary Shares ("ADS") since close of business
27 July 2020 and will reopen on 4 August 2020. The short closure (which was announced on 15 July 2020) is for administrative purposes,
to allow JPMorgan to effect a ratio change to the Company's sponsored Level I American Depositary Receipt ("ADR") programme.
former ratio of five (5) ordinary shares to one (1) ADS has been changed to two (2) ordinary shares per one (1) ADS and is effective
on 31 July 2020. Therefore, ADR holders will receive 1.5 additional ADRs for every one (1) ADR held.
will be no change to the underlying ordinary shares.
StemPrintER Demerger
Company continues to advance plans for the potential demerger of StemPrintER to a new company which will be called "AccuStem".
The Company is currently seeking tax clearances for the proposed transaction and will then put the proposals to shareholders for
approval. The record date for entitlement to participate in any distribution will be a date after the date on which the posting
of the circular is announced (and not before). A further announcement will be made in due course.
Company decision on cancellation of the trading of its shares on AIM has been postponed due to the continuing impact of COVID-19.
No final decision on this matter will now be taken until at least Q4 2020.
Company continues to pursue all of its clinical candidates in line with previous announcements. There are no new developments
to report at the current time, either in relation to the COVID-19 focused projects, or the other ongoing studies.
announced this morning, Dr Kunwar Shailubhai will be giving an overview of Tiziana's development pipeline and upcoming milestones
during an investor webinar, hosted by RedChip Companies, today at 4:00 p.m. U.S. Eastern. A live Q&A session with Shailubhai
will follow the presentation. To register for the free webinar, please visit: https://www.redchip.com/corporate/webinar_register/68.
new information will be given at this webinar (which is pre-recorded, save for the Q&A session) and which is intended merely
to give attendees a summary overview of the Company's activities (condensing the more extensive information available on the Company's
Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses
on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases.
In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's
Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal
antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD),
psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development
of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially
for treatment of COVID-19 patients.
| Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
| Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner | +44 (0)20 7213 0880 |
| Optiva Securities Limited (Broker) Robert Emmet | +44 (0)20 3981 4173 |
RedChip Companies Inc.